These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32745642)

  • 1. Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma.
    Roll W; Müther M; Sporns PB; Zinnhardt B; Suero Molina E; Seifert R; Schäfers M; Weckesser M; Stegger L; Beule AG; Stummer W; Rahbar K
    World Neurosurg; 2020 Nov; 143():e391-e399. PubMed ID: 32745642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
    Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
    Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
    Schmidt M; Fischer E; Dietlein M; Michel O; Weber K; Moka D; Stennert E; Schicha H
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1571-80. PubMed ID: 12458390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
    Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
    Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours).
    Puranik AD; Kulkarni HR; Singh A; Baum RP
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1223-30. PubMed ID: 25822655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
    Zovato S; Kumanova A; Demattè S; Sansovini M; Bodei L; Di Sarra D; Casagranda E; Severi S; Ambrosetti A; Schiavi F; Opocher G; Paganelli G
    Horm Metab Res; 2012 May; 44(5):411-4. PubMed ID: 22566197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
    Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S
    ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide receptor radionuclide therapy in head and neck paragangliomas – Report of 14 cases.
    Estêvão R; Duarte H; Lopes F; Fernandes J; Monteiro E
    Rev Laryngol Otol Rhinol (Bord); 2015; 136(4):155-8. PubMed ID: 29400037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With
    Huot Daneault A; Desaulniers M; Beauregard JM; Beaulieu A; Arsenault F; April G; Turcotte É; Buteau FA
    Front Endocrinol (Lausanne); 2021; 12():705271. PubMed ID: 34367072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Response to 177 Lu-DOTATATE PRRT in a 9-Year-Old Child With Metastatic Carotid Body Paraganglioma.
    Yadav MP; Raju S; Ballal S; Bal C
    Clin Nucl Med; 2024 Jan; 49(1):e33-e34. PubMed ID: 37976428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
    Thiis-Evensen E; Poole AC; Nguyen HT; Sponheim J
    BMC Cancer; 2020 May; 20(1):466. PubMed ID: 32448245
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
    Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
    Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
    Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
    [No Abstract]   [Full Text] [Related]  

  • 16. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors.
    Basu S; Fargose P
    J Nucl Med Technol; 2016 Dec; 44(4):248-250. PubMed ID: 27634982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
    Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
    Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.
    Gabriel M; Nilica B; Kaiser B; Virgolini IJ
    J Nucl Med; 2019 Apr; 60(4):524-529. PubMed ID: 30115690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma.
    Deville A; Pinigina I; Al Mansour L; Abeillon J; Tordo J
    Clin Nucl Med; 2022 Jan; 47(1):e71-e73. PubMed ID: 34115704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.